Zimislecel by Vertex Pharmaceuticals: status and timeline

Milestones

Next · Manufacturing process analysis pause

First patient dosed2021Complete.
First patient achieves insulin independenceQ1 2022Complete.
12-month efficacy data: 83% insulin independence, 0 severe hypos2023Complete.
Phase 1/2/3 enrollment completeQ2 2025Complete.
Manufacturing process analysis pauseTarget Q1 2026Current milestone.
FDA, EMA, MHRA BLA submissionTarget 2026Not yet reached.

Most important updates

Vertex provides pipeline update on Zimislecel: Phase 1/2/3 trial fully enrolled, regulatory submissions on track for 2026Jan 2026

Upcoming

Q1 2026Manufacturing process analysis pause (next)
2026FDA, EMA, MHRA BLA submission
2027FDA decision and potential approval

Current obstacles

Manufacturing complexity and costGrowing and differentiating stem cells at GMP scale requires sophisticated facilities and process control; production cost per patient is still high.
Islet cell durabilityZimislecel islets must produce insulin for years. Long-term follow-up data will reveal whether insulin independence persists or requires re-dosing.

Physics limits

Stem cell maturation in cultureInducing pluripotent stem cells to differentiate into functional, glucose-responsive beta cells with the same fidelity as native islets remains challenging; purity and functional maturity drive efficacy.
Immune system tolerance to allogeneic cellsEven encapsulated, non-self cells may trigger an immune response over time. The body's ability to tolerate foreign cells limits long-term persistence without immunosuppression.

How it works

3 parts

Stem cells

Pluripotent cells to islets

Pluripotent stem cells are grown and differentiated into beta cells that produce insulin in response to glucose.

Infusion

Portal vein delivery

Zimislecel is infused into the portal vein. Islet cells settle in the liver and produce insulin.

Tolerance

Immune-tolerant infusion

Islets are infused into sites where the immune system tolerates them, avoiding the need for immunosuppression.

Spec sheet

Spec	Zimislecel
Insulin independence at 1 year	83%^R (reported)
Severe hypoglycemic episodes	0^R (reported)
Mean HbA1c reduction	7.8% to 6.0%^R (reported)

^R reported by the company

Update log

1 update

Jan 2026

Major: Vertex provides pipeline update on Zimislecel: Phase 1/2/3 trial fully enrolled, regulatory submissions on track for 2026PressTest

About Vertex Pharmaceuticals

The team behind Zimislecel

Vertex Pharmaceuticals

Cystic fibrosis, sickle cell, type 1 diabetes, gene editing

Vertex is a leader in rational drug design with blockbusters in cystic fibrosis (Kalydeco, Trikafta). It co-markets Casgevy, the first approved CRISPR therapy for sickle cell and beta thalassemia. Zimislecel, its stem-cell islet therapy for type 1 diabetes, is in Phase 3.

Vertex's CF franchise (Kalydeco, Trikafta) is the market leader; Casgevy is the first approved CRISPR therapy.
Revenue in 2025 reached $12 billion; net income $3.95 billion; CEO Reshma Kewalramani.
Zimislecel for type 1 diabetes showed 83% insulin independence in early trials; Phase 3 enrollment complete, BLA expected 2026.

vrtx.com (opens vrtx.com)Company profile →

Founded: 198937 yrs
Headquarters: United States
Status: Public
Listed: VRTX (opens google.com)NASDAQ
Valuation: $121Bmarket capAug 2026
Staff: ~5,839Apr 2025
Raised: $27M1 round
Last round: Initial Public Offering · $27MJul 1996
Works in: BiotechGene editing & therapy
Coverage: 1 program · 1 updatelatest 1 Jan 2026checked 10 Oct
Partners: CRISPR Therapeutics (opens crisprtx.com)
People: Reshma Kewalramani (opens en.wikipedia.org)Chief Executive Officer and PresidentCharles Wagner (opens investors.vrtx.com)Chief Operating and Financial Officer

Spec

Zimislecel

Insulin independence at 1 year

83%^R (reported)

Severe hypoglycemic episodes

0^R (reported)

Mean HbA1c reduction

7.8% to 6.0%^R (reported)